ZEJULA (niraparib) logo

Product menu

Image of fictitious patient

Quality of life

In PRIMA, ZEJULA (niraparib) preserved QoL for over 30 treatment cycles for women living with advanced ovarian cancer comparable to placebo1

ZEJULA preserved overall HRQoL in PRIMA vs placebo over 30 cycles1*

*Statistical significance not assessed.

Symptom-related quality of life in PRIMA (data cut-off: primary analysis; FOSI):1†‡

A graph showing health-related QoL/patient-reported outcomes of Zejula (niraparib) vs placebo

Figure adapted from González-Martín A, et al. 2019.
†Exploratory analysis, results should be interpreted with caution.1
‡FOSI is a validated eight-item measure of symptom response to treatment, including lack of energy, vomiting, pain, nausea, stomach
swelling, worsening condition, quality of life as assessed by the patient, and cramps in the stomach area.2

WHAT ABOUT ZEJULA EFFICACY?

Find out more

ZEJULA dosing

ZEJULA safety profile

Zejula (niraparib) is indicated3

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Abbreviations

FIGO, Federation of Gynaecology and Obstetrics; FOSI, Functional Assessment of Cancer Therapy-Ovarian Symptoms Index; HRQOL; Health Related Quality of Life; QoL, quality of life.

References

  1. González-Martín A, et al. N Engl J Med. 2019;381(25):2391–2402.
  2. FACIT.org. Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index – 8-item version. Available at: https://www.facit.org/measures/FOSI (accessed September 2022).
  3. Zejula (niraparib) Summary of product characteristics (Last Accessed: April 2023).

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2024 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

April 2024 | PM-GB-NRP-WCNT-220020 (V2.0)